RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Breakthrough Therapy (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC21H19FN6O2

InChIKeyIIXWYSCJSQVBQM-LLVKDONJSA-N

CAS Registry1454846-35-5

Clinical Trials associated with Lorlatinib

NCT07617337

/ Not yet recruitingPhase 1

A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of AQUA07 Monotherapy and Combination Therapy in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.

Start Date31 Jul 2026

Sponsor / Collaborator

Chugai Pharmaceutical Co., Ltd.

NCT07556549

/ Active, not recruitingNot Applicable

RETROSPECTIVE CHART REVIEW STUDY OF FIRST LINE LORLATINIB IN LOCALLY ADVANCED/METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA

The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC.
The participants included in this study are:
* Aged 18 years or more
* diagnosed with a/mNSCLC
* confirmed with testing for ALK-positive
* have started first-line lorlatinib treatment during the patient selection period
In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.

Start Date18 May 2026

Sponsor / Collaborator

Pfizer Inc.

JPRN-jRCT2031260134

/ Not yet recruitingPhase 1

A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF AQUA07 MONOTHERAPY AND COMBINATION THERAPY IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

Start Date01 May 2026

Sponsor / Collaborator

Chugai Pharmaceutical Co., Ltd.

100 Clinical Results associated with Lorlatinib

100 Translational Medicine associated with Lorlatinib

100 Patents (Medical) associated with Lorlatinib

887

Literatures (Medical) associated with Lorlatinib

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer in Italy

Article

Author: Pasello, Giulia ; Novelli, Giuseppe ; Rumi, Filippo ; Di Virgilio, Roberto ; Bearz, Alessandra ; Basile, Michele ; Di Brino, Eugenio ; Valentini, Ilaria

BACKGROUND:

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with high central nervous system penetration and activity against resistance mutations. Although its clinical efficacy as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) has been demonstrated, its economic value within the Italian healthcare system remains to be fully established. This study evaluated the cost-effectiveness of lorlatinib compared with alectinib as first-line therapy in Italy.

METHODS:

A partitioned survival model with three health states (progression-free, progressed disease, and death) was developed from the Italian National Health Service and societal perspectives over a 30-year time horizon. Clinical efficacy inputs were derived from the CROWN trial and indirect treatment comparisons using network meta-analysis. Costs (2026 euros) included drug acquisition, subsequent treatments, healthcare resource use, adverse events, end-of-life care, and societal costs. Health outcomes were expressed as life-years (LYs) and quality-adjusted life-years (QALYs). Deterministic, probabilistic, and scenario analyses were conducted to assess uncertainty.

RESULTS:

In the base case, lorlatinib was dominant over alectinib, providing higher benefits (+2.01 LYs; +1.66 QALYs) at lower costs (-€19,210 per patient). This finding was robust across pricing scenarios. Probabilistic sensitivity analysis showed an almost 98,40% probability of cost-effectiveness at Italian willingness-to-pay thresholds.

CONCLUSIONS:

From both NHS and societal perspectives, lorlatinib represents a cost-saving and clinically superior first-line treatment option compared with alectinib for patients with ALK-positive advanced NSCLC in Italy.

31 Dec 2026·Lung Cancer Management

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China

Article

Author: Zhu, Fanfan ; Li, Hongchao ; Xue, Jing ; Le, Hannah ; Duan, Jia ; Hu, Bingqi ; Li, Dingsiman ; Rifi, Nada ; Dong, Peng ; Luan, Luan

AIM:

To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs).

METHODS:

A survey of 105 clinical experts across 23 Chinese regions evaluated healthcare resource utilization (HCRU). Total annual costs with TKIs were calculated by weighting the management costs of patients with and without BM using the cumulative incidence rate (CIR) of BM from ALK-TKI clinical trials.

RESULTS:

First-year management cost averaged ¥24,974 per-patient without BM versus ¥89,859 per-patient with BM, saving ¥64,885. Subsequent years saved ¥33,231. Applying 12-month CIR of BM, the annual costs per-patient were ¥26,791 for 1 L lorlatinib versus ¥46,516 for crizotinib in the intention-to-treat (ITT) population. Subgroup analysis showed annual costs of ¥25,623 per-patient with lorlatinib in those without BM and ¥29,775 in those with BM. Alectinib's and brigatinib's costs were ¥31,073 and ¥32,760 respectively, using the 12-month CIR of BM. Lorlatinib's cost savings increased progressively over 1-4 years. Limited CIR beyond 12 months existed for brigatinib and ensartinib. Results from the Asian group's CIR aligned with global trials.

CONCLUSION:

Due to lower BM CIR, lorlatinib showed higher BM management cost savings compared to crizotinib and alectinib in Chinese 1 L patients.

01 Jul 2026·LUNG CANCER

Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors

Article

Author: Davis, Ian J ; Baid, Drishti ; Liu, Xiaofan ; Jin, Shihan ; Romley, John A ; Nieva, Jorge J ; Mudumba, Rahul

OBJECTIVE:

To estimate the comparative effectiveness of first-line (1 L) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK-positive non-small cell lung cancer (NSCLC) in the United States.

METHODS:

We conducted a retrospective cohort study using Optum's de-identified Clinformatics® Data Mart Database (2016-2024). Patients with lung cancer ICD-10 codes and pharmacy claims for ALK TKIs were eligible if aged ≥ 18 years, continuously enrolled ≥ 6 months before initiation, and treated after each drug's FDA approval. Outcomes included time-to-next (targeted) treatment or death (TTNTD) and overall survival (OS). Propensity scores were constructed for pairwise comparisons and applied using overlap weighting (OW) as the primary specification and inverse probability of treatment weighting (IPTW) as alternative specification.

RESULTS:

Among 940 patients initiating 1 L therapy (crizotinib n = 449, alectinib n = 417, brigatinib n = 30, ceritinib n = 8, lorlatinib n = 36), alectinib had the longest reached median TTNTD (33.5 months; 95% CI, 24.6-46.3) and OS (46.5 months; 95% CI, 39.0-NR) in unadjusted analyses. In overlap-weighted analyses, alectinib was associated with significantly longer TTNTD (HR 0.50; 95% CI, 0.41-0.61) and OS (HR 0.58; 95% CI, 0.47-0.71) versus crizotinib. Comparison of alectinib vs lorlatinib statistically insignificantly favored lorlatinib (TTNTD HR 2.02; 95% CI, 0.92-4.46; OS HR 1.29; 95% CI, 0.58-2.83).

CONCLUSION:

Alectinib demonstrated a clear survival advantage over crizotinib, consistent with trial findings. Lorlatinib showed potential benefit over alectinib, though limited by sample size and wide confidence intervals. This study provides the largest claims-based analysis of 1 L ALK TKIs and may help guide differentiation among agents with equivalent guideline placement.

News (Medical) associated with Lorlatinib

09 Jun 2026

·www.prnewswire.com

Lung Cancer Research Foundation Announces Request for Proposals Open for ALK-Positive Lung Cancer Research Grant

Research Award Focused on Accelerating Treatment Options for People with ALK-Positive Lung Cancer NEW YORK, June 9, 2026 /PRNewswire/ -- The Lung Cancer Research Foundation announced today that a new, two-year, $300,000 research award focused on accelerating treatment options for people with anaplastic lymphoma kinase (ALK) fusion-driven non-small cell lung cancer (NSCLC) is now open for investigator submission. Continue Reading ALK-positive Research Grant RFP In 2007, scientists discovered that a genetic abnormality, or fusion, called EML4-ALK plays a key role in driving a subset of NSCLC. This led to the development of targeted drugs called ALK inhibitors, the first of which was FDA-approved in 2011. The latest of these, lorlatinib, is a third-generation inhibitor designed to overcome resistance to earlier drugs. In a major clinical trial (CROWN), lorlatinib outperformed an older drug, crizotinib, showing longer progression-free survival and better control of brain metastases. At the most recent ASCO conference, results of seven years of follow-up showed that more than half of the patients enrolled in the trial have stable disease, the best result ever reported for a single targeted therapy in advanced NSCLC. While this is great news, resistance eventually develops in all patients, leaving chemotherapy and clinical trials as the only remaining options, as immunotherapy has largely been ineffective in ALK-positive NSCLC. That is why LCRF is committed to funding research that will combat resistance when it does eventually occur. There is a critical need to better understand why these tumors grow, how they respond to treatment, and why resistance develops. The 2026 LCRF Award on Advancing Breakthroughs in ALK-Positive Lung Cancer grant mechanism will focus on the science behind ALK rearrangements as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with ALK positive lung cancer that have the potential to increase survivorship. Given the specific interest in the development of novel therapies that could benefit this group of patients in the near- term, a resulting clinical trial from this research would be ideal. Proposals for this grant should include a program of correlative, translational research that will enhance the understanding of ALK-driven lung cancers. Bruce Dunbar, a member of LCRF's Board of Directors and ALK-positive lung cancer survivor, said, "Grants like this are critical to ensuring there are more options and new approaches to treating ALK-positive NSCLC that has stopped responding to existing therapies. More investment in research means more ALK patients will live longer and better lives and the closer we'll get to a cure." "Science has already given many people with ALK-positive lung cancer years they wouldn't otherwise have had. But we cannot stop there," remarked Kathryn A. O'Donnell, PhD, Associate Professor, Department of Molecular Biology, UT Southwestern Medical Center, Co-leader, Development and Cancer Program, Simmons Comprehensive Cancer Center and Chair of the LCRF Scientific Advisory Board. "Resistance will eventually develop, and we have an obligation to be ready. Funding this research now is how we make sure the next breakthrough will happen." The 2026 LCRF Award on Advancing Breakthroughs in ALK-Positive Lung Cancer grant was made possible by funding from members of the lung cancer community, led by Colleen Conner Ziegler, chair of LCRF's board of directors and ALK-positive lung cancer survivor; the Murgatroyd family, who lost their daughter at the age of 24 to ALK-positive lung cancer; Mary Ann Tighe and Dr. David Hidalgo, in honor of Dr. Randi Warren, an ALK-positive lung cancer survivor; David Cornbrooks, co-founder of the Sweat for Breath Foundation and an ALK-positive lung cancer survivor; an independent grant from Pfizer; and many other generous donors. Submissions for this mechanism will be reviewed through a two-step process: Letters of Intent will be accepted until midnight on July 15, 2026; if selected, investigators will then be chosen to submit full proposals, subject to rigorous review by LCRF's Scientific Advisory Board. More details about the Request for Proposal, along with eligibility, requirements, and deadlines can be found at LCRF.org/FundingOpportunities. About the Lung Cancer Research Foundation (LCRF) The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 450 research grants, totaling nearly $53 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information, visit lcrf.org. Contact: Sheila Sullivan, Sr. Director, Marketing & Communications [email protected] SOURCE Lung Cancer Research Foundation 21% more press release views with Request a Demo

ImmunotherapyClinical ResultDrug Approval

09 Jun 2026

·www.fiercebiotech.com

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer

GSK CEO Luke Miels said the deal “will strengthen our operating profit ... through the dolutegravir loss of exclusivity period.”\n GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers. The FDA is set to rule on whether to approve Nuvalent’s ROS1 inhibitor zidesamtinib in September and reach a decision on the biotech’s ALK inhibitor neladalkib in November. With two near-approval assets, plus a phase 1 HER2 inhibitor and preclinical programs, the deal offers near-term growth drivers to ease the pressure GSK could face as generics erode sales of a key HIV drug from 2028 to 2030.“Subject to FDA approvals, the acquisition will deliver revenue growth from 2027. This is what our investors have been asking,” GSK CEO Luke Miels said on a call with the media early Tuesday morning. “It will strengthen our operating profit for GSK through the dolutegravir loss of exclusivity period.”Nuvalent filed for FDA approval of zidesamtinib in ROS1-positive non-small cell lung cancer (NSCLC) patients who have previously received a tyrosine kinase inhibitor (TKI). Before accepting GSK’s offer, the biotech said (PDF) it planned to apply to expand the label in the second half of the year to include patients without prior TKI exposure.Zidesamtinib could pose a threat to Pfizer’s TKI inhibitor Xalkori, which Nuvalent named as the first-line standard of care. Treatment guidelines also recommend (PDF) Roche’s Rozlytrek, Bristol Myers Squibb’s Augtyro and Nuvation Bio’s Ibtrozi, especially against brain metastases. Nuvalent has identified improved durability and reduced central nervous system side effects as ways to differentiate zidesamtinib.The FDA is reviewing neladalkib in TKI-pretreated, ALK-positive NSCLC. Nuvalent is enrolling patients in a phase 3 trial that is pitting the ALK inhibitor against Roche’s Alecensa in TKI-naive patients. Alecensa is the first-line standard of care and Pfizer’s Lorbrena is the preferred second-line treatment, according to Nuvalent. Miels named a recent seven-year analysis of Pfizer’s phase 3 Crown study as a driver of GSK\'s interest in neladalkib. The data showed Pfizer’s Lorbrena “has very good efficacy but a very, very difficult side effect profile to manage,” Miels said. Because patients are often relatively young, the downsides to a drug that impacts their ability to care for their kids and lead active lives are particularly severe, Miels said.The duration of treatment factored into GSK’s valuation of Nuvalent. The target mutations are found in a small subset of patients—about 3% to 5% of people with NSCLC are ALK-positive—but patients who are eligible for treatment spend longer on the drugs than is typical for many cancers. That means there are “very long tails to these products,” Miels said. About 1% to 3% of patients have ROS1 mutations. GSK sees “multiblockbuster potential” for zidesamtinib and neladalkib, leading it to agree to pay $124 a share to buy the biotech. Nuvalent’s stock closed at $88.49 on Monday. The outlay is well beyond the $2 billion to $4 billion deal range that Miels targeted after becoming CEO early this year. Yet the GSK leader maintained that the Nuvalent buyout is in line with the types of deals the company has been pursuing and striking. The difference is that instead of paying up to $4 billion for a biotech with one attractive asset, GSK is paying $10.6 billion for a company with multiple molecules of interest. “If you take apart the components, it\'s consistent with our approach so far,” Miels said. If zidesamtinib or neladalkib wins FDA approval, the deal will accelerate GSK’s entry into lung cancer and provide a potential launchpad for its B7-H3 antibody-drug conjugate (ADC) risvutatug rezetecan. GSK started a phase 3 trial of the ADC in small cell lung cancer last year.

Phase 3AcquisitionPhase 1Drug ApprovalADC

09 Jun 2026

·allsci.com

Chugai enters post-lorlatinib ALK resistance race with AQUA07 trial

Japan-based Chugai Pharmaceutical Co., Ltd. (TSE: 4519) has registered a first-in-human Phase I clinical trial of AQUA07, an oral investigational drug whose mechanism has not been publicly disclosed, in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on at least one prior ALK inhibitor. The AQUA07 clinical trial is notable for its parallel-arm structure: one arm evaluates AQUA07 as monotherapy, while a second tests it in combination with lorlatinib, Pfizer’s third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI). The design suggests Chugai may be positioning AQUA07 to address resistance mechanisms that emerge after exposure to later-generation ALK inhibitors — a setting where durable options remain limited. The Phase I, open-label, multicenter study (NCT07617337) is expected to enroll approximately 102 adults with locally advanced unresectable or metastatic ALK-positive NSCLC, according to the trial record. Patients must have received at least one prior ALK TKI, though those treated exclusively with crizotinib — the first-generation agent — are excluded, effectively enriching the population for individuals who have progressed on second- or third-generation inhibitors such as alectinib, brigatinib, or lorlatinib itself. The study is structured in two parallel dose-escalation parts: Part A evaluates AQUA07 monotherapy, and Part B evaluates AQUA07 in combination with lorlatinib, with each arm seeking to establish the recommended Phase II dose and maximum tolerated dose. Recruitment is anticipated to begin in Q3 2026, with primary completion targeted for August 2030. Secondary endpoints include pharmacokinetic profiling of both AQUA07 and lorlatinib, as well as preliminary efficacy measures — objective response rate, progression-free survival, and duration of response — assessed per RECIST v1.1. The biological rationale for AQUA07 cannot be fully characterized from available public sources; Chugai has not disclosed the compound’s molecular target or mechanism of action ahead of trial initiation, which is consistent with the company’s practice for early-stage internal programs. The oral route of administration and classification as a small-molecule drug are confirmed by the trial record, suggesting a kinase inhibitor-type modality, though this remains an inference. The decision to pair AQUA07 with lorlatinib in a dedicated dose-escalation arm — rather than simply evaluating monotherapy activity — implies the compound may act on a pathway distinct from or complementary to direct ALK kinase inhibition, potentially addressing bypass signaling or resistance mutations that limit the durability of ALK TKI monotherapy. Chugai has prior expertise in ALK-positive NSCLC through its development of alectinib (Alecensa), a second-generation ALK inhibitor now widely used as a first-line standard of care. In the post-lorlatinib resistance setting, the competitive field is sparse but active. The most advanced program is Nuvalent‘s neladalkib (NVL-655), a brain-penetrant next-generation ALK inhibitor designed to overcome a broad range of resistance mutations, including compound mutations that can emerge following sequential ALK TKI treatment. The agent is currently under US FDA review following positive pivotal data from the ALKOVE program. Chugai’s decision to evaluate AQUA07 both as monotherapy and in combination with lorlatinib suggests a potentially differentiated strategy, although the absence of a disclosed molecular target makes direct comparisons premature. Trial identifier: NCT07617337. Sponsor: Chugai Pharmaceutical Co., Ltd. Status: Not yet recruiting. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

100 Deals associated with Lorlatinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11012	Lorlatinib	L01XE44	DB12130

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	United States	Pfizer Inc.	02 Nov 2018
Non-Small Cell Lung Cancer	Japan	Pfizer Inc.	21 Sep 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Marginal Zone Lymphoma	Phase 2	United States	Pfizer Inc.	01 May 2020
ALK-positive anaplastic large cell lymphoma	Phase 2	Italy	Pfizer Inc.	28 Sep 2019
Anaplastic Large-Cell Lymphoma	Phase 2	Italy	Pfizer Inc.	28 Sep 2019
metastatic non-small cell lung cancer	Phase 2	United States	Pfizer Inc.	18 Dec 2015
metastatic non-small cell lung cancer	Phase 2	Japan	Pfizer Inc.	18 Dec 2015
metastatic non-small cell lung cancer	Phase 2	Australia	Pfizer Inc.	18 Dec 2015
metastatic non-small cell lung cancer	Phase 2	South Korea	Pfizer Inc.	18 Dec 2015
metastatic non-small cell lung cancer	Phase 2	Spain	Pfizer Inc.	18 Dec 2015
Advanced Lung Non-Small Cell Carcinoma	Phase 2	United States	Pfizer Inc.	08 Jan 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	Japan	Pfizer Inc.	08 Jan 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05740943 (LORIN, ASCO2026)	Phase 2	Non-small cell lung cancer stage III Neoadjuvant ALK fusion	43	Lorlatinib	kpdsrvcusj(cvafbwrrpx) = oagokqqbsu hqsctkxmlf (tkvjckpbka ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	ALK positive Lung Cancer	35	Lorlatinib 25 mg	zullrqtpee(ghwmfszksl) = xewpkvjbfm mbpnuisulv (tauqfvvehl ) View more	Positive	29 May 2026
NCT03052608 (CROWN, ASCO2026)	Phase 3	ALK positive Non-Small Cell Lung Cancer First line ALK+	296	Lorlatinib 100 mg once daily	aizcveeruq(kaahyhaqnp) = Treatment-related AEs (TRAEs) led to permanent treatment discontinuation in 5% of pts with lorlatinib and 6% with crizotinib mkfrmyygto (ohxthljadt ) View more	Positive	29 May 2026
				Crizotinib 250 mg twice daily
ASCO2026	Not Applicable	ALK positive Non-Small Cell Lung Cancer First line	82	Lorlatinib	kjakgqojgd(nygyeencny) = oarwfvxxzd fjqjjabhgx (irftdutuab, NR - NR) View more	Positive	29 May 2026
NCT04362072 (Pubmed \| Future Oncol)	Phase 4	Second line ALK-positive	71	Lorlatinib 100 mg once daily	dkewibehyf(cfrmsoergw) = jsgnwkbhzx aivijmdnay (eghftzuwhj, 31 - 55) View more	Positive	21 Apr 2026
				Lorlatinib 100 mg once daily (central nervous system metastases)	dkewibehyf(cfrmsoergw) = jsvvaqohqg aivijmdnay (eghftzuwhj )
AACR2026	Not Applicable	ALK positive Non-Small Cell Lung Cancer First line ALK-positive	60	Lorlatinib (good response)	jvdfguqfht(qkzsumkkef) = vamdlufnco ojilcnepci (syezqoylza ) View more	Positive	19 Apr 2026
				Lorlatinib (limited response)	jvdfguqfht(qkzsumkkef) = zqtxkwbzxw ojilcnepci (syezqoylza ) View more
ESMO_ELCC2026	Not Applicable	Non-Small Cell Lung Cancer	170	Lorlatinib (ALK+ or ROS1+ NSCLC + long responders)	nzxsxbgjwi(fytzplaqrt) = mdbvbhbvzo mljrvrpisz (apcilclzwu ) View more	Positive	25 Mar 2026
ESMO_ELCC2026	Not Applicable	ALK positive Non-Small Cell Lung Cancer First line	108	First-line lorlatinib	sdidfrhigd(lvfmbxazed): HR = 0.32 (95.0% CI, 0.15 - 0.67), P-Value = 0.003 View more	Positive	25 Mar 2026
				Sequential second-generation ALK TKI followed by lorlatinib
ESMO_ELCC2026	Not Applicable	ALK positive Non-Small Cell Lung Cancer	146	Lorlatinib	bwrzpkqfeh(cwqfwtbang) = cshnljeyci pashcxsuxp (byrenisymc ) View more	Positive	25 Mar 2026
				Brigatinib	bwrzpkqfeh(cwqfwtbang) = yaxfsnwasu pashcxsuxp (byrenisymc ) View more
NCT06893354 (LORTAN, ESMO_ASIA2025)	Phase 2	First line \| Neoadjuvant ALK+	20	Lorlatinib	wmdrtuuprp(qyiczmhfgl) = birfilrxng sjdlqmdpyu (vxuemgxwfb ) View more	Positive	05 Dec 2025
				Lorlatinib + Chemotherapy	cjarpkozuw(mfxtnnfmbe) = ygigrrvrga mzklxlryly (ixqduwyhbl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis